Nanoconjugate based on polymalic acid for tumor targeting.

  title={Nanoconjugate based on polymalic acid for tumor targeting.},
  author={Julia Y. Ljubimova and Manabu Fujita and Natalya M. Khazenzon and Bong-Seop Lee and Sebastian Wachsmann-Hogiu and Daniel L. Farkas and Keith L. Black and Eggehard Holler},
  journal={Chemico-biological interactions},
  volume={171 2},

Figures from this paper

Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery.
Delivery of antisense oligonucleotides to a tumor-specific angiogenic marker using Polycefin resulted in significant inhibition of tumor angiogenesis and increase of animal survival.
Nanoconjugate Platforms Development Based in Poly(β,L-Malic Acid) Methyl Esters for Tumor Drug Delivery.
Viability of cultured brain and breast cancer cell lines indicated moderate toxicity that increased with methylation and partially methylated poly(β,L-malic acid) copolyesters are suitable as nanoconjugate platforms for drug delivery.
Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity.
The characterization of a novel, targeted, nanobiopolymeric conjugate based on biodegradable, nontoxic, and nonimmunogenic PMLA offers a preclinical proof of concept for use of the PMLA nanoplatform for combination cancer therapy.
Toxicity and efficacy evaluation of multiple targeted polymalic acid conjugates for triple-negative breast cancer treatment
PLA-based nanodrugs of the Polycefin™ family passed multiple toxicity and efficacy tests in vitro and in vivo on preclinical level and may prove to be optimized and efficacious for the treatment of cancer patients in the future.
Polymalic acid nanobioconjugate for simultaneous inhibition of tumor growth and immunostimulation in HER2/neu-positive breast cancer✩
A new nanobioconjugate of the Polycefin family of anti-cancer drugs based on biodegradable and non-toxic polymalic acid (PMLA) was engineered for a multipronged attack on HER2/neu-positive breast cancer cells and was capable of eliciting anti-tumor activity in immunocompetent mice bearing IL-2.
Preparation of poly(β-L-malic acid)-based charge-conversional nanoconjugates for tumor-specific uptake and cellular delivery
The electrostatic interaction between the positively charged HDPEPM nanoconjugates and the negatively charged cell membrane significantly enhanced their cellular uptake, resulting in the enhanced anticancer activity.
Preparation of Two Types of Polymeric Micelles Based on Poly(β-L-Malic Acid) for Antitumor Drug Delivery
It is suggested that the P2 (crew cut) micelles possess better stability than that of the P1 (star) mouselles and might be a potential drug delivery system for cancer therapy.
Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.
Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid).
A Combination of Tri-Leucine and Angiopep-2 Drives a Polyanionic Polymalic Acid Nanodrug Platform Across the Blood-Brain Barrier.
A biodegradable nontoxic β-poly(l-malic acid) (PMLA or P) is synthesized as a scaffold to chemically bind the BBB crossing peptides Angiopep-2, MiniAp-4, and the transferrin receptor ligands cTfRL and B6 and can now be functionalized with intra-brain targeting and drug treatment moieties that are aimed at molecular pathways implicated in neurological disorders.


Polycefin, a new prototype of a multifunctional nanoconjugate based on poly(beta-L-malic acid) for drug delivery.
In vitro experiments using two human glioma cell lines U87MG and T98G demonstrated that Polycefin was delivered into the tumor cells by a receptor-mediated endocytosis mechanism and was able to inhibit the synthesis of laminin-8 alpha4 and beta1 chains at the same time.
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
The potential utility of nanoparticle-aptamer bioconjugates for a therapeutic application is demonstrated and remarkable efficacy and reduced toxicity as measured by mean body weight loss (BWL) in vivo are demonstrated.
Intracellular drug delivery by sulfatide-mediated liposomes to gliomas.
Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes.
A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers.
In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug.
Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier.
Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles
The preparation of transferrin-modified nanoparticles containing DNAzymes (short catalytic single-stranded DNA molecules) for tumor targeting as well as their biodistribution using various methods of administration in the mouse are reported on.
DNA polyplexes based on degradable oligoethylenimine-derivatives: combination with EGF receptor targeting and endosomal release functions.